Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data
Headache The Journal of Head and Face Pain2023Vol. 63(3), pp. 418–428
Citations Over TimeTop 10% of 2023 papers
David Kudrow, Rima M. Dafer, David W. Dodick, Amaal J. Starling, Jessica Ailani, Carrie Dougherty, Kavita Kalidas, Feng Zhang, Rohini Jeswani, Nishil Patel, Ani C. Khodavirdi
Abstract
Ischemic CV and cerebrovascular AEs were uncommon and the incidence rates were similar across the 10-year CV risk categories. This analysis helps provide more detail on the CV safety of erenumab.
Related Papers
- → Cranial Magnetic Resonance Imaging Findings in Patients With Migraine(2004)40 cited
- → The Similarities and Differences of Migraine with Aura and Migraine Without Aura: A Preliminary Study(1991)46 cited
- → Migraine and Oral Contraceptives(1997)27 cited
- Study on the relationship between migraine and right-to-left shunt(2014)
- → Faculty Opinions recommendation of Opening of ATP sensitive potassium channels causes migraine attacks with aura.(2021)